ALK and non-small cell lung carcinoma: As it can be difficult to tackle drug resistance in ALK-rearranged NSCLC tumors following ALK-TKI interventions due to tumor heterogeneity, it may be best to first limit the number of DT cells based on knowledge of the molecular mechanisms underlying intrinsic resistance and early ALK-TKI refractoriness4.